IRIS UniCatt

Voso, Maria Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.535
EU - Europa 5.205
AS - Asia 4.183
SA - Sud America 715
AF - Africa 103
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 8
Totale 16.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.396
DE - Germania 1.889
SG - Singapore 1.702
CN - Cina 1.414
SE - Svezia 734
PL - Polonia 591
BR - Brasile 581
UA - Ucraina 451
IT - Italia 412
FR - Francia 351
VN - Vietnam 326
GB - Regno Unito 201
IE - Irlanda 184
IN - India 151
FI - Finlandia 126
ID - Indonesia 110
RU - Federazione Russa 91
JP - Giappone 89
TR - Turchia 75
HK - Hong Kong 61
CA - Canada 53
BD - Bangladesh 51
IQ - Iraq 41
MX - Messico 41
NL - Olanda 38
AR - Argentina 37
PK - Pakistan 31
CO - Colombia 29
ZA - Sudafrica 29
BE - Belgio 19
CI - Costa d'Avorio 19
ES - Italia 19
AU - Australia 17
EC - Ecuador 16
VE - Venezuela 16
AT - Austria 14
KR - Corea 14
UZ - Uzbekistan 13
CL - Cile 12
GR - Grecia 11
IR - Iran 11
MA - Marocco 11
AE - Emirati Arabi Uniti 10
CZ - Repubblica Ceca 10
JO - Giordania 10
CH - Svizzera 9
HN - Honduras 9
IL - Israele 9
KE - Kenya 9
LT - Lituania 9
PY - Paraguay 9
SA - Arabia Saudita 9
CR - Costa Rica 8
EG - Egitto 8
PH - Filippine 8
TN - Tunisia 8
BG - Bulgaria 7
JM - Giamaica 7
PE - Perù 7
RO - Romania 7
TH - Thailandia 7
KZ - Kazakistan 6
DO - Repubblica Dominicana 5
ET - Etiopia 5
MY - Malesia 5
PT - Portogallo 5
BO - Bolivia 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
AL - Albania 3
AM - Armenia 3
AZ - Azerbaigian 3
BH - Bahrain 3
DZ - Algeria 3
GE - Georgia 3
HR - Croazia 3
HU - Ungheria 3
NI - Nicaragua 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
SN - Senegal 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BW - Botswana 2
DK - Danimarca 2
EU - Europa 2
GH - Ghana 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PR - Porto Rico 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
Totale 16.751
Salva come PNG Salva come JPEG
Città #
Singapore 945
Chandler 736
Ashburn 667
Warsaw 572
San Jose 542
Jacksonville 329
Beijing 234
Nanjing 216
San Mateo 207
Dearborn 188
Houston 179
Ann Arbor 174
Dublin 174
Los Angeles 174
Wilmington 166
Hangzhou 162
Woodbridge 161
New York 134
Cambridge 122
Fairfield 120
Nürnberg 112
Chicago 106
Jakarta 101
Munich 101
Hanoi 100
Ho Chi Minh City 100
Lauterbourg 100
Seattle 97
Milan 92
Hefei 80
Nanchang 80
Lawrence 72
Bremen 71
Buffalo 71
Tokyo 67
Dallas 63
Boston 62
Cattolica 59
Hong Kong 57
São Paulo 57
Frankfurt am Main 55
Moscow 55
Redwood City 54
Kunming 50
Santa Clara 48
Izmir 44
Rome 40
Shanghai 39
The Dalles 39
Lancaster 34
Marseille 32
Shenyang 32
Tianjin 31
University Park 30
London 29
Salt Lake City 29
Auburn Hills 28
Leawood 28
Changsha 25
Helsinki 25
Jiaxing 25
Princeton 25
Guangzhou 23
Hebei 23
Fremont 22
Falls Church 21
Kent 21
Zhengzhou 21
Council Bluffs 20
Norwalk 20
Orem 20
Abidjan 19
Mountain View 18
Brussels 17
Da Nang 17
Baghdad 16
Boardman 16
Chatsworth 16
Elk Grove Village 16
Montreal 16
Paris 16
Atlanta 15
Belo Horizonte 15
Brooklyn 15
Detroit 15
Rio de Janeiro 15
Pune 14
Augusta 13
Denver 13
Haiphong 13
Jinan 13
Lanzhou 13
Philadelphia 13
Tampa 13
Amsterdam 12
Johannesburg 12
Mexico City 12
Nuremberg 12
San Francisco 12
Las Vegas 11
Totale 9.256
Salva come PNG Salva come JPEG
Nome #
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 436
Incidence of acute myeloid leukemia after breast cancer 386
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 366
Fanconi anemia gene variants in therapy-related myeloid neoplasms 327
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 311
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 282
Therapy-related leukemias and myelodysplasia : susceptibility and incidence. 281
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 270
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 249
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 243
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 242
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 240
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 236
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 235
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 235
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 223
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 218
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 212
Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia 212
Why methylation is not a marker predictive of response to hypomethylating agents 202
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 198
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 197
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 193
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 191
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 190
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 190
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 188
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 186
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 185
Epigenetic changes in therapy-related MDS/AML 184
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 183
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 183
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 181
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 177
Clonal evolution in therapy-related neoplasms 177
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 176
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 175
Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia 173
Similarities and differences between therapy-related and elderly acute myeloid leukemia 172
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 172
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 172
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 171
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 170
Primary plasma cell leukemia followed by testicular plasmacytoma 165
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 161
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 160
Iron in Hodgkin's lymphoma 159
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 158
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 158
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 157
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 156
PU.1 and CEBPA expression in acute myeloid leukemia. 156
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 155
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 155
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 154
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 154
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 151
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 151
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis 150
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 150
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 149
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 148
Small lymphocytic lymphoma in a patient with Fabry disease 143
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 142
Outcome of therapy-related myeloid neoplasms treated with azacitidine 139
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 139
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 136
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 135
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 135
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 130
Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial) 129
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 129
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 128
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 127
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 127
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 126
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. 124
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 124
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 121
Therapy-related myeloid neoplasms: Clinical perspectives 120
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 115
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 114
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 114
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 113
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 111
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 110
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 106
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 103
Therapy-related myeloid neoplasms 99
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 98
Efficacy and toxicicty of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer 91
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes 88
Telomerase activity in human hematopoietic progenitor cells 87
Telomerase activity in human hematopoietic progenitor cells 86
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 85
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 84
Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far? 80
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 78
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 75
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile 64
Totale 16.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022933 113 100 5 30 75 38 24 165 45 83 123 132
2022/20231.989 250 281 154 361 120 249 70 181 234 7 59 23
2023/2024835 40 259 15 20 33 148 34 34 13 24 109 106
2024/20251.956 45 61 151 60 184 32 99 73 280 135 567 269
2025/20264.823 679 123 234 386 786 337 885 350 437 331 156 119
2026/202763 63 0 0 0 0 0 0 0 0 0 0 0
Totale 16.895